作者
Nicolò Pernigoni,Elena Zagato,Arianna Calcinotto,Martina Troiani,Ricardo Pereira Mestre,Bianca Calì,Giuseppe Attanasio,Jacopo Troisi,Mirko Minini,Simone Mosole,Ajinkya Revandkar,Emiliano Pasquini,Angela Rita Elia,Daniela Bossi,Andrea Rinaldi,Pasquale Rescigno,Penny Flohr,Joanne Hunt,Antje Neeb,Lorenzo Buroni,Christina Guo,Jonathan Welti,Matteo Ferrari,Matteo Grioni,Josée Gauthier,Raad Z. Gharaibeh,Anna Palmisano,Gladys Martinetti Lucchini,Eugenia D’Antonio,Sara Merler,Marco Bolis,Fabio Grassi,Antonio Esposito,Matteo Bellone,Alberto Briganti,María Rescigno,Jean‐Philippe Theurillat,Christian Jobin,Silke Gillessen,Johann S. de Bono,Andrea Alimonti
摘要
Microbes hijack prostate cancer therapy Androgens such as testosterone and dihydrotestosterone are essential for male reproduction and sexual function. Androgens can also influence the growth of prostate tumor cells, and androgen deprivation therapy (ADT) either by surgical means (castration) or pharmacological approaches (hormone suppression), is the cornerstone of current prostate cancer treatments. Pernigoni et al . found that when the body was deprived of androgens during ADT, the gut microbiome could produce androgens from androgen precursors (see the Perspective by McCulloch and Trinchieri). Gut commensal microbiota in ADT-treated patients or castrated mice produced androgens that were absorbed into the systemic circulation. These microbe-derived androgens appeared to favor the growth of prostate cancer and helped to facilitate development into a castration- or endocrine therapy–resistant state. —PNK